Layoffs Coming Again, This time MASS EXODUS!

Quote












KK wont save you. RL wont even read your emails. Your DM wont even tell you whats going on. This dictatorship of a company is blowing up REAL quick.

Grab what ever you can. Grab whats left of this company. What ever they offer you in severance, just take it.

Pretty soon the only thing that will be left to grab is your regret. Even that is will be short changed.

I know its hard to move on. Heck I'm still alive writing this.

See you on the flip side. #MDGA
 






anonymous said:
The wrap of Q4, earnings per share down, while a puffer of financial statements showing increased cash flow for shareholders. - The classic Enron scheme.

They move around money, while debt to cash flow ratio shows the company is making a surplus. DSI's managerial overhead are in the shitter folks!

RL took a decrease in salary so did KK.

The company is going down so fast, I dont even know how I am still here writing this.

We can never fix the problems this sink hole has. Its been a nightmare here.

Let that sink in.

Let that sink in.

This Wednesday be prepared for the email again. You have been warned. Take severance while you can.

-HO
Click to expand...


You should leave... Coming from HO I can say no one took a pay cut, and the news was good today for DSI. Let that sink in.
 






anonymous said:
You should leave... Coming from HO I can say no one took a pay cut, and the news was good today for DSI. Let that sink in.
Click to expand...

TAKE A LOOK AT THE ACCOUNTING STATEMENTS RELEASED.

THIS IS ALL PUBLIC INFORMATION.

DSI DOESNT KEEP ANYONE IN THE LOOP. YOU NEED TO DO IT YOURSELF IF YOU WANT TO KNOW WHAT IS GOING ON. I SURE AM.

DONT LET THEM SWINDLE YOU INTO ANOTHER PYRAMID SCHEME.

THESE SCHEMATICS HAVE LOST THEIR LUNIES!!!

SHAME SHAME SHAME!
 






This analysis says it all...

Announcement:
Moody's: Japanese pharmaceutical companies' expiring drugs patents could prompt strategic alliances

Global Credit Research - 20 Oct 2016

Tokyo, October 20, 2016 -- Moody's Japan K.K. says that the expiry of key drug patents over the next 1-3 years will pressure the revenues of the rated Japanese pharmaceutical companies, and could prompt the formation of strategic allegiances and acquisitions.

"While all three rated pharmaceuticals companies are implementing countermeasures, we believe it will be difficult for them to compensate for the loss in revenue from these key products, which account for around 11%-34% of their respective revenues -- a credit negative," says Kailash Chhaya, a Moody's Vice President and Senior Analyst.

"As such, we believe the companies will pursue strategic alliances with other pharmaceutical companies with niche capabilities in certain geographies or products and to pursue acquisitions, both in an effort to maintain low- to mid-single-digit revenue growth," adds Chhaya.

Moody's conclusions are contained in its just released report, titled "Pharmaceuticals -- Japan: Key Patent Expiries to Pressure Revenues, Drive Strategic Alliances/Acquisitions".

Moody's report highlights that all three pharmaceutical companies that it rates in Japan -- Takeda Pharmaceutical Company Limited (A1 stable), Astellas Pharma Inc. (A1 stable) and Daiichi Sankyo Company, Limited (A1 negative) -- have patents expiring for some of their key global products between 2016 and 2019.

Daiichi Sankyo will lose its patents on the Olmesartan family of products (antihypertensive agent) in the US in late 2016, and the EU and Japan in 2017. Takeda will lose its US patent on top-selling Velcade (for multiple myeloma) in late 2017. Astellas will lose its patent on Vesicare (for overactive bladder) in the US, EU and Japan between 2018 and 2020 and Tarceva (for non-small cell lung cancer and pancreatic cancer) in the US in 2019.

Moody's expects revenues from these drugs could fall 30%-40% in the year following the launch of the generic versions.

Despite various countermeasures, including rapid market development of recently launched high-potential products, effective late-stage pipeline commercialization and cost cuts, Moody's expects all three will experience revenue shortfalls.

The shortfall will likely be greatest for Daiichi Sankyo, because the Olmesartan family of products -- an antihypertensive agent whose patent will expire in the US in late 2016 and in the EU and Japan in 2017 -- accounted for around 28.8% of consolidated revenue in the fiscal year ended March 2016 (FYE3/2016).

In the absence of material new internal sources of revenue, Moody's expects the pharmaceutical companies will be strongly incentivized to pursue strategic alliances or acquisitions.

The primary goal of acquisitions will likely be to strengthen the companies' existing therapeutic categories, rather than to takeover large competitors with unrelated businesses.

Moody's says such transactions could pressure the companies' ratings if they are large and mostly debt-funded, while smaller acquisitions of niche high potential products and late-stage pipelines would conversely be positive for their ratings.
 




























































anonymous said:
GG developed and delivered Savaysa. It's US sales that are under performing. The same product is doing very well in Asia and the EU. RL and KK are not providing solutions. The only solution they have is to cut cost (e.g., Sales).
Click to expand...

You know we;re a Japanese company right, we kind of have an advantage there, it's a single payer system and there is no lou, it's in one market in europe, only germany go take a look and yo'll see, you have no idea what you are talking about you just post things that are completely untrue
 












anonymous said:
GG developed and delivered Savaysa. It's US sales that are under performing. The same product is doing very well in Asia and the EU. RL and KK are not providing solutions. The only solution they have is to cut cost (e.g., Sales).
Click to expand...
Hey idiot, you must work in Edison and don't understand the US market
 












Top Bottom
Back
Quote